September 21, Merck, a leading global technology company, announced the opening of the first phase of its EUR 29 million biosafety testing laboratory in China, a virus clearance validation laboratory. The 5,000 square meter center is Merck's first laboratory of its kind in China.

Cytiva, backed by a $1.5 billion investment from its parent company, the Danaher Group, continued its expansion tear with the acquisition of CEVEC Pharmaceuticals.

Suzhou 4a Biotech Co., Ltd. has recently completed a Pre-A round of financing of tens of millions (CNY).

Illumina said on Wednesday that its Illumina Accelerator program has invested in six new startups from around the world.

Recently, Wuhan YZY Biopharma Co., Ltd completed a 200 million CNY Pre-C round of financing. This round of financing was completed by the joint investment of Wuhan Hi-Tech, Hubei Science Technology Investment and Optics Valley Financial Holding Group.

Visby Medical said on Wednesday that it has added $35 million to its Series E financing round, bringing its total proceeds from the round to more than $135 million.

Since Beckman Coulter began to develop in China more than 40 years ago, it has continued to increase local investment, firmly helped China's laboratory medicine, realized the localization of a number of products, and is committed to promoting leading science and technology to more people.

Recently, Shenzhen Eurekabio Technology Co., Ltd. (hereinafter referred to as "Eurekabio") announced that it had completed the 100 million CNY of round B financing.

On May 20, the customs statistical data platform updated the import and export data. The export value of China’s COVID-19 reagents in May was 1.394 billion yuan, which is less than 10% of the value in January.

Chinese sequencing technology company Axbio said on Monday that it has secured $100 million in Series B financing.